In this work we describe a forward genetic approach to identify mutations that affect blood vessel development in the zebrafish. By applying a haploid screening strategy in a transgenic background that allows direct visualization of blood vessels, it was possible to identify several classes of mutant vascular phenotypes. Subsequent characterization of mutant lines revealed that defects in Vascular endothelial growth factor (Vegf) signaling specifically affected artery development. Comparison of phenotypes associated with different mutations within a functional zebrafish Vegf receptor-2 ortholog (referred to as kdr-like, kdrl) revealed surprisingly varied effects on vascular development. In parallel, we identified an allelic series of mutations in phospholipase c gamma 1 (plcg1). Together with in vivo structure-function analysis, our results suggest a requirement for Plcg1 catalytic activity downstream of receptor tyrosine kinases. We further find that embryos lacking both maternal and zygotic plcg1 display more severe defects in artery differentiation but are otherwise similar to zygotic mutants. Finally, we demonstrate through mosaic analysis that plcg1 functions autonomously in endothelial cells. Together our genetic analyses suggest that Vegf/Plcg1 signaling acts at multiple time points and in different signaling contexts to mediate distinct aspects of artery development.
Introduction
The circulatory system provides oxygenation and waste removal for developing organs and tissues, while serving as a conduit for hormones and components of the immune system (Cleaver and Krieg, 1999) . In addition, the endothelial cells lining nascent blood vessels also serve as a source for important inductive and guidance signals during organogenesis (Alt et al., 2006; Lammert et al., 2001) . Accordingly, blood vessel function is essential for vertebrate embryonic development (Cleaver and Krieg, 1999) . As organisms transition from embryonic to adult stages, new blood vessel formation (neovascularization) becomes more limited and in most cases this process is associated with pathological conditions in the adult. As with normal tissue and organs during embryonic development, ischemic tissue or nascent tumors require increased vascularization and are known to produce and secrete numerous angiogenic molecules that promote blood vessel growth (Semenza, 2003) . In most cases, the signals that promote neovascularization in these pathological settings in adults are the same that are used by the embryo (Cleaver and Krieg, 1999) . Furthermore, the signaling molecules and cellular mechanisms by which blood vessels form have been evolutionarily conserved . Accordingly, it is has been possible to gain significant insights on pathological blood vessel formation through the study of embryonic vascular development in vertebrate model systems.
Among the important signaling molecules that are responsible for neovascularization in both embryonic and adult settings are several receptor tyrosine kinase families. These include receptors for vascular endothelial growth factors (Vegf), angiopoietins and the membranebound ephrin ligands (Yancopoulos et al., 2000) . Vegf-A initiates and induces endothelial cell differentiation at the earliest stages of blood vessel development (Ferrara et al., 2003) . Vegf-A acts by binding Vegfr-2, an endothelial cell specific receptor tyrosine kinase (Quinn et al., 1993) . Mice lacking either Vegf-A or Vegfr-2 display severely reduced numbers of endothelial cells and fail to form blood vessels (Carmeliet et al., 1996; Shalaby et al., 1995) . Loss of specific Vegf-A isoforms or endothelial autonomous ablation of Vegf signaling has revealed later roles for this signaling pathway in arterial endothelial cell differentiation and promoting endothelial cell survival, respectively (Carmeliet et al., 1999; Lee et al., 2007; Stalmans et al., 2002) . Furthermore, Vegf-A is also required for angiogenic sprouting and plays an important role in modulating vascular permeability in both adult and embryonic stages (Bates and Harper, 2002; Ferrara et al., 2003) . In parallel to the Vegf signaling pathway, the angiopoietins and their receptor, Tie2, mediate subsequent sprouting and maturation of the vascular network at later stages of embryonic development. Angiopoietin/Tie2 signaling plays an important role in crosstalk between endothelial cells lining the blood vessels and associated vascular smooth muscle cells during angiogenic sprouting Maisonpierre et al., 1997; Suri et al., 1996; Suri et al., 1998) . Similarly, the Eph receptor tyrosine kinases and their ligands, referred to as ephrins, mediate cell-cell signaling between distinct cell types in the developing vascular system . Eph-ephrin signaling plays an important role in mediating the interface and separation between arteries and veins (Gerety et al., 1999; Wang et al., 1998) , as well as endothelial cell interaction with surrounding mesenchymal cells (Adams et al., 1999; Yancopoulos et al., 1998) .
For the most part, the functional analysis of these and other signaling pathways during vascular development has proceeded largely through reverse genetic approaches using the mouse as a model system. More recently, the zebrafish has emerged as an ideal model system for studying embryonic vascular development (Roman and Weinstein, 2000) . The transparency and external fertilization of the zebrafish embryo, coupled with the use of endothelial cell-specific fluorescent protein transgenes have allowed an unprecedented view of blood vessel formation in a live organism (Beis and Stainier, 2006; Roman et al., 2002; Siekmann et al., 2008) . These particular aspects of the zebrafish embryo have made it a tractable vertebrate model for forward genetic screening. Early screens relying on the straightforward visualization of blood circulation in the zebrafish embryo led to the identification of mutations that affected cardiovascular morphogenesis or function Stainier et al., 1996) . More recently, the use of transgene-assisted screens (Jin et al., 2007) has allowed more subtle characterization of defective vascular phenotypes in mutant zebrafish embryos. The ability to easily generate thousands of progeny embryos coupled with the increasing quality of genomics tools has facilitated genetic mapping and identification of genes responsible for many of these phenotypes (Patton and Zon, 2001) .
In this study, we describe a haploid transgenic screen in zebrafish embryos to identify mutants that perturb normal vascular development. This screening approach allowed robust and specific detection of several different classes of mutant vascular phenotypes and the majority of these were subsequently observed in diploid embryos. Subsequent characterization and cloning of the genes responsible for these mutant phenotypes revealed that the zebrafish Vegf receptor, kdr-like (kdrl), and phospholipase c gamma 1 (plcg1) were essential for artery development. Interestingly, detailed phenotypic analysis of different kdrl alleles suggested diverse roles for this receptor during development of blood vessels. Parallel analysis of plcg1 alleles, along with in vivo structure/function experiments, indicated a crucial role for Plcg1 catalytic function downstream of receptor tyrosine kinases during artery development. Furthermore, analysis of maternal-zygotic plcg1 mutant embryos suggested an early role for Vegf/Plcg1 signaling during arterial specification, while mosaic analysis revealed an endothelial autonomous role for plcg1 during vascular morpohgenesis. Taken together our results demonstrate the utility of a transgenic haploid screening approach to identify mutants affecting vascular development in the zebrafish and underscore the diverse roles of Vegf/Plcg1 signaling during artery development.
Materials and methods

Fish handling and care
All zebrafish were maintained according to standard protocols (Westerfield, 1993) and in accordance with University of Massachusetts Medical School IACUC guidelines.
Transgenic and mutant lines
Nomenclature for the zebrafish Vegf receptor orthologs was assigned based on recently described guidelines (Bussmann et al., 2008) . The um19 allele is a 4 base pair deletion in exon 2 of kdrl that was generated by targeted mutagenesis using zinc finger nucleases and is described elsewhere (Meng et al., 2008) . The Tg(fli1a:egfp) y1 line has been described elsewhere . To generate zebrafish embryos with red fluorescent blood vessels, we constructed a plasmid containing a chimeric endothelial enhancer-promoter fragment driving dsRed-Express via Gateway cloning into a Tol2 plasmid backbone (Villefranc et al., 2007) . The resulting plasmid (pTolfli1ep:dsredex) was co-injected into 1-cell stage wild type zebrafish embryos along with mRNA encoding the Tol2 Transposase (Kawakami et al., 2004) . Embryos with the highest and least mosaic expression were grown to adulthood and founders were identified by out-crossing. The Tg(fli1ep:dsredex) um13 line was derived from a single founder.
Mutagenesis and screening
ENU mutagenesis was performed based on previously described protocols (Solnica-Krezel et al., 1994) . Briefly, we treated homozygous Tg(fli1a:egfp) y1 adult males with 3 mM N-ethyl-N-nitrosourea (ENU) for 1 hour once a week for a total of 4 weeks. Following a two-week recovery, fish were bred to wild type females to purge mutagenized gametes that usually harbor gross chromosomal aberrations (Imai et al., 2000) . ENU-treated males were then crossed to homozygous Tg(fli1a:egfp) y1 females to generate an F1 generation. Beginning at 6 months of age, F1 Tg(fli1a:egfp) y1 females were used to generate haploid embryos by performing in vitro fertilization (Westerfield, 1993) using UV irradiated sperm. Each individual F1 Tg (fli1a:egfp) y1 female that successfully gave viable haploids was maintained in an individual tank. Subsequently, Tg(fli1a:egfp) y1 embryos were screened at 30 hours post fertilization and again at 50 hpf for defects in segmental artery formation, as well as overall morphology using a stereo dissection microscope equipped with epifluorescence. F1 Tg(fli1a:egfp) y1 females that gave clutches of embryos in which fifty percent displayed a mutant vascular phenotype were subsequently out-crossed to TL males to generate a map cross. Females that gave mutant phenotypes that exhibited general morphological defects or necrosis were not maintained. Genetic linkage mapping and candidate cloning of genes was carried out as described elsewhere (Lawson et al., 2003; Roman et al., 2002) .
Phenotypic analysis and microscopy
All diploid mutant embryos were analyzed at 30 hpf using a dissection microscope equipped with epifluorescence (Leica MZFLIII, 1x PlanApo) to determine presence of segmental arteries. Embryos were also observed with transmitted light at 55 hpf to observe circulatory patterns and overall morphology. Vascular morphology defects were documented in more detail using a Leica DMIRE2 microscope equipped with a TCS SP2 confocal laser scanning system (Objective: HC PL APO 20x/0.70 CS, dry). In most cases, vertical projections of confocal stacks were generated using Leica Confocal Software (LCS). Alternatively, vertical projections were generated using the Imaris software package (Bitplane). Sprout length was measured in 3-dimensional stacks using Imaris. For this purpose, 6 pairs of segmental artery sprouts were counted in at least 3 embryos from 3 different clutches. Length was measured as distance of a perpindicular line from the dorsal wall of the dorsal aorta to the distal end of the segmental artery. Overall morphology was documented by capturing digital images using transmitted light on a MZFLIII dissection microscope equipped with a Zeiss Axiocam mRC digital camera using Axiovision software (Zeiss). More detailed morphological imaging was performed by differential interference contrast (DIC) microscopy using a Zeiss Axioskop2plus compound microscope (Achroplan 20x/0.5 water; Achroplan 40x/0.8 water) equipped with a Zeiss Axiocam hRC digital camera. All images were exported from Axiovision, LCS, or Imaris as TIF files and imported into Photoshop CS2 (Adobe) to generate figures.
Riboprobes
Antisense riboprobes against ephrinb2a, dll4, and notch3, were generated as described previously (Lawson et al., 2001; Siekmann and Lawson, 2007) . Whole mount in situ hybridization was performed as described elsewhere (Hauptmann and Gerster, 1994) . DIC images of stained embryos were captured as described above.
Generation of germ cell plcg1 mutants
To generate adults bearing plcg1 deficient germ cells, we utilized the germ-line replacement strategy described elsewhere (Ciruna et al., 2002) . Briefly, embryos from an incross of nontransgenic plcg1 y18 carriers were injected with mRNA encoding EGFP with the 3′UTR from the nanos transcript. In parallel, wild type embryos were injected with a morpholino targeting the dead end gene to ablate host germ cells. Donor cells from the margin of sphere stage embryos derived from putative plcg1 y18 carriers were transplanted into the margin of host wild type embryos. Donor and host embryos were then allowed to develop until 24 to 48 hpf. Host embryos were grown to adulthood if the corresponding donor embryo was found to be mutant for plcg1 by visual inspection and the host embryos displayed evidence of transplanted germ cells as indicated by green fluorescence. Putative maternal (M) or paternal (P) mutant founders were identified by crossing them to heterozygous plcg1 y18 mutant carriers. In all cases, Mplcg1 y18 and Pplcg1 y18 carriers displayed fully penetrant plcg1 mutant phenotypes indicating that all germ cells were mutant.
Plcg1 rescue experiments
Previously described mutations in the SH2 (Ji et al., 1999) and SH3 (Ye et al., 2002) domains of Plcg1 were introduced into zebrafish plcg1 coding sequence by overlapping PCR and all constructs were validated by sequencing. Mutant constructs were generated in the pCS-mtplcg1 backbone (Lawson et al., 2003) . All plasmids were linearized with Not I and mRNA synthesized using the mMessage mMachine kit (Ambion) to drive transcription from the SP6 promoter. We injected 400 pg of mRNA into 1-cell stage embryos derived from an incross of plcg1 y18 heterozygous carriers. As controls, embryos were injected with mRNA encoding wild type Plcg1, or left uninjected. Embryos were scored at 30 hpf for segmental artery formation; embryos were classified as having no segmental arteries (SeA−), partial segmental arteries, with no dorsal longitudinal anastomotic vessel (SeA+DLAV−), or wild type (SeA+DLAV+). At 55 hpf, embryos were scored for blood circulation and classified with normal circulation (circ+), evidence of shunting between the dorsal aorta and posterior cardinal vein (partial), or no circulation (circ−). Following phenotypic analysis, all embryos were subjected to PCRscreening for genotyping.
To generate expression constructs for activated forms of Akt or MAP2K1, we first generated Gateway entry clones. A constitutively membrane-localized form of Akt was PCR-amplified from a plasmid template (kindly provided by Fumihiko Urano, UMass Medical School) using the following primers: 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCGTTTAGCTTATGGGGAG and 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTAGGCTGTGCCACTGGCTGAGT, where Akt coding sequence are underlined and the endogenous start codon is in bold. An activated form of human MAP2K1 was amplified from plasmid template (kindly provided by Roger Davis, UMass Medical School) using primers 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTccAAAATGCCCAAGAAGAAGC and 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTTTAGACGCCAGCAGCATGGGT; hMAP2K1 sequence is underlined, endogenous start codon is in bold. In both cases, the forward primer contains an attB1 site, while the reverse primer contains an attB2 site. PCR products were subjected to BP cloning to generate pMEmAkt and pMEactMAP2K1 entry clones, which were sequence validated. Entry clones were then used in Gateway LR reactions to generate expression clones. For actMAP2K1, we constructed N-terminal monomeric Cherry fusion proteins by recombining pMEactMAP2K1 with either pCSCherDest (to give pCS-mcheractMAP2K1)or pTolfli1epCherDest (to give pTol-fli1ep:mcher-actMAP2K1) (Villefranc et al., 2007) . For mAkt, we utilized multisite Gateway cloning to generate a tandem, unfused mAkt-mCherry cassette using the viral 2A peptide sequence (Provost et al., 2007) . For this purpose, we recombined pMEmAkt with pCSDest2 (Villefranc et al., 2007) and p3E-2a-mcherry (kindly provided by Chi-Bin Chien, University of Utah) to give pCS-mAkt-2a-mcher. To generate an endothelial cell specific construct, we recombined pMEmAkt with p5Efli1ep, which contains a chimeric fragment of a fli1a enhancer and promoter (Villefranc et al., 2007) , pDest Tol2pA (Kwan et al., 2007) , and p3E-2a-mcherry to give pTolfli1ep:mAkt-2a-mcherry. We utilized pCS-mCher-actMAP2K1 and pCS-mAkt-2a-mcherry for mRNA synthesis as described elsewhere (Villefranc et al., 2007) and mRNA was injected at 1-to 2-cell stage into wild type embryos. For pTol-fli1ep:mAkt-2a-mcher and pTolfli1ep:mcher-actMAP2K1, we co-injected 25 pg of circular plasmid DNA with 25 pg Tol2 transposase mRNA into 1-cell stage embryos derived from an incross of plcg1 y13 heterozygous carriers. Injected embryos were observed for segmental artery formation and circulation as described above.
Genotyping
The plcg1 y13 mutation eliminates a PstI site within the X-catalytic domain. PCR was performed using primers 5′-CTGCGTTCAGCTATCCCATC and 5′-CCTCTTGAGCTGGTGTGGCGA and the resulting product was digested with PstI. The plcg1 y16 mutation eliminates an EagI in the N-terminal SH2 domain. For y16 genotyping, primers 5′-GTATGGACCAGCATGTGACGGAG and 5′-CTACAAAGGTCTCGCTCTCCCGC were used for PCR and the resulting fragment was digested with EagI. For genotyping the plcg1 y18 allele, we amplified a CA repeat within plcg1 (primers: 5′-TGTAGGATCTGAGGTTTGAT and 5′ TGAGATCCTTGAGCCTGGGG) that was polymorphic in our background strain. Alternatively, we utilized a single nucleotide polymorphism (SNP) within a StyI site in plcg1 in our crosses (5′-GCAACGAGTTCGAGATGAAGC and 5′-GTGTGGACGCATAGCCCTC). Genotyping of the kdrl alleles was performed as described elsewhere (Covassin et al., 2006; Meng et al., 2008) .
Mosaic analysis
For mosaic analysis of plcg1 deficient cells in wild type vasculature, donor Tg(fli1a:egfp) y1 embryos were prepared by injecting with the lineage tracer Cascade Blue (Molecular Probes/ Invitrogen) and 7.5 ng of a plcg1 morpohlino targeting the exon 1 splice donor site (Lawson et al., 2003) at 1-to 2-cell stage. At sphere stage, cells were removed from donor embryos and transferred to wild type Tg(fli1ep:dsredex) um13 hosts using a glass capillary. For analysis of wild type cells in plcg1-deficient vasculature, donor Tg(fli1a:egfp) y1 embryos were injected with the lineage tracer Cascade Blue. Subsequently, donor cells were placed into Tg (fli1ep:dsredex) um13 embryos that had been injected at the 1-cell stage with the plcg1 morpohlino. As a control, cells for Cascade Blue-injected wild type Tg(fli1a:egfp) y1 embryos were transplanted into uninjected wild type Tg(fli1ep:dsredex) um13 host embryos. In all cases, embryos were grown to 26 to 28 hpf at which time position of GFP+ donor cells was determined through visualization by confocal microscropy as described above. Emission from GFP, dsRedEx, and Cascade Blue was acquired by sequential scanning using a 488 nm, 561 nm and 405 nm laser line, respectively. Subsequently, confocal stacks were used to generate vertical projection and overlays using the included Leica software, Imaris, or Photoshop CS2.
Results
A haploid transgenic screen to identify mutants that affect embryonic vascular development
Previous forward screening strategies to identify vascular mutants in zebrafish have relied on observation of circulatory defects in F3 embryos as a primary screen Jin et al., 2007; Stainier et al., 1996) . However, the two-generation breeding scheme used in F3 screens is labor-and cost-intensive and can take several years to screen sufficient numbers of genomes. In an effort to more easily screen for vascular mutants in zebrafish, we took advantage of the ability to generate haploid embryos to allow screening of progeny from F1 females. Additionally, we utilized Tg(fli1a:egfp) y1 zebrafish to allow direct visualization of putative vascular phenotypes in developing haploid embryos derived from F1 females.
To induce mutations in the male zebrafish germline, we treated homozygous Tg (fli1a:egfp) y1 males with N-ethyl-N-nitrosourea (ENU). Subsequently, we used ENU-treated males to generate F1 families ( Figure 1A ). To identify mutations that would lead to blood vessel defects, we generated haploid embryos from individual Tg(fli1a:egfp) y1 F1 females and screened for segmental artery formation at 1 or 2 days post fertilization. In general, we found that the overall morphology of haploid Tg(fli1:egfp) y1 zebrafish embryos was relatively normal, although body length was shortened and somite formation, as well as head development was often mildly perturbed ( Fig. 1B and data not shown). Despite these mild abnormalities, trunk blood vessel morphology and segmental artery formation was robust in wild type Tg(fli1:egfp) y1 haploid embryos allowing for straightforward identification of mutant vascular phenotypes ( Fig. 1C-G ). In total, we screened approximately 1200 mutagenized genomes and identified 17 females that produced clutches in which half of the haploid embryos displayed specific defects in vascular morphology. In all cases, general morphology of the mutant embryos was comparable to their wild type siblings (data not shown). We were able to identify 4 classes of mutant phenotypes in clutches of haploid embryos from F1 Tg (fli1:egfp) y1 females. Class I mutants such as y10, displayed a complete loss of segmental artery formation ( Figure 1D , Table 1 ) while the level of transgene expression was comparable to wild type siblings indicating the presence of endothelial cells within the presumptive dorsal aorta and posterior cardinal vein. In Class II mutants, such as y16, we observed partial segmental artery formation ( Figure 1E ). A single Class III mutant, um7, displayed ectopic branching of segmental arteries ( Figure 1F ). The y11 mutant (Class IV) exhibited the most severe effect on vascular development with a complete loss of segmental arteries, defective formation of the major trunk vessels ( Figure 1G ), as well as loss of cranial blood vessels (data not shown).
To confirm that the vascular defects observed in haploids would persist in diploid embryos and to facilitate genetic mapping, we out-crossed putative F1 female mutant carriers to a genetically diverse wild type line (TL; Figure 1A ). We were able to obtain viable F2 families from 14 out of 17 females. In clutches of embryos from 10 out of the 14 families, we observed defective vascular phenotypes that were similar or identical to those observed in mutant haploid embryos (see below). Subsequent bulk segregant analysis, fine genetic mapping and/or candidate cloning revealed 10 distinct alleles in 4 genes that were responsible for the observed vascular defects. The y11 mutation lies in the endothelial cell specific transcription factor, ets-related protein (etsrp), leading to global defects in endothelial gene expression, apoptosis of endothelial cells, and defects in vascular morphogenesis (Pham et al., 2007) . Consistent with the ectopic sprouting defects observed in um7 mutants, we find that this mutation maps to the plexind1 locus (data not shown), a gene previously implicated in proper segmental artery patterning in zebrafish (Torres-Vazquez et al., 2004) . We found that Class I and II mutants that displayed defects in segmental artery formation mapped to two genes implicated in Vegf signaling, plcg1 and kdrl. Based on our previous findings concerning the role of Vegf in artery development, we focused on the detailed genetic and phenotypic characterization of these mutants.
Mutations in a zebrafish Vegf receptor-2 ortholog cause defects in artery development
We have previously found that a mutation in a zebrafish Vegf receptor, referred to as kdrlike (previously referred to as flk1 or kdra) is responsible for partial segmental artery defects associated with the y17 mutant identified in our haploid screen (Table 1( Covassin et al., 2006) ). Of the other segmental artery mutants identified in our screen, only um6 failed to complement y17 (data not shown), indicating that it also was a mutation in kdrl. Interestingly, the um6 mutation appeared to lead to more severe defects in segmental artery formation in haploid embryos than those associated with y17 (Table 1) . Therefore, to better evaluate the effects of the kdrl um6 and kdrl y17 mutations on vascular development, we compared them to a null kdrl allele that we generated through targeted mutagenesis using zinc finger nucleases (Meng et al., 2008) . The um19 allele is a 4 base pair deletion in exon 2 of kdrl and introduces a frameshift that truncates the Kdrl receptor tyrosine kinase in the extracellular domain.
We first compared defects in vascular morphogenesis associated with each kdrl allele in mutant embryos bearing the Tg(fli1:egfp) y1 transgene. In wild type siblings at 30 hours post fertilization, a basic vascular network consisting of the dorsal aorta, segmental arteries and the dorsal longitudinal anastomotic vessel (DLAV) was evident ( Figure 2A ). The kdrl um6 mutation appeared to have the most severe effect on segmental artery formation leading to variable formation of partial segmental arteries in most embryos ( Figure 2B , white arrows indicate partial segmental arteries). In many cases, small filopodial extensions were observed at the usual site of segmental artery formation, but sprouts failed to emanate from the dorsal aorta ( Figure 2B , red arrowheads). kdrl um6 mutant embryos also failed to display a distinctly separated dorsal aorta and posterior cardinal vein and instead a single major trunk vessel was evident ( Figure 2B , red bracket). We observed that defective segmental artery formation due to the null kdrl um19 mutation was similar to kdrl um6 mutant embryos, although partial sprouts were consistently observed within every segment ( Figure 2C ). Interestingly, morphogenesis of the dorsal aorta and posterior cardinal vein was largely normal in kdrl um19 mutant embryos ( Figure 2C ). Embryos mutant for kdrl y17 displayed the mildest segmental artery defects, with variable formation of DLAVs and partial segmental artery formation evident ( Figure 2D ). However, dorsal aorta morphogenesis appeared abnormal as we observed its discontinuous formation in kdrl y17 mutant embryos ( Figure 2D , red arrowhead). This observation is consistent with our previous finding of arteriovenous shunting between the dorsal aorta and posterior cardinal vein in kdrl y17 mutant embryos (Covassin et al., 2006) . Quantification of segmental artery length in each mutant confirmed that the um6 mutation most severely affected segmental artery formation, while um19 and y17 had increasingly milder effects ( Figure 2E ). Subsequent molecular analysis of the kdrl coding sequence in um6 mutant embryos revealed a T to G transversion resulting in a missense mutation that changed cysteine to glycine at amino acid 1117 within the Kdrl cytoplasmic domain (Table 1 ). This cysteine residue is identical in the related zebrafish vegf-receptor 2 ortholog, kdr, as well as related Vegf receptors in zebrafish, mouse, and human ( Figure 2F ).
Our analysis of vascular morphology in kdrl mutants revealed a surprisingly differential effect on angiogenic formation of segmental arteries and dorsal aorta morphogenesis. To further assess how these alleles affect vascular morphogenesis and function, we assayed circulatory defects in kdrl mutant embryos. At 55 hpf, wild type embryos displayed a functional circulatory system that carries hemoglobinized red blood cells ( Figure 3A and data not shown). By contrast, kdrl um6 mutant embryos failed to exhibit any active circulation and display pericardial edema ( Figure 3B and data not shown). Closer inspection of embryos derived from kdrl um6 heterozygous carriers revealed that approximately five percent of all embryos with otherwise normal circulatory flow displayed cranial hemorrhage (compare Figures 3C and D; Figure 3H ). Subsequent genotyping of these embryos revealed that they were heterozygous for the T to G transversion (data not shown) suggesting that the kdrl um6 mutation can act as a mild dominant negative. Despite the moderate severity of the segmental artery defects in kdrl um19 mutant embryos, this mutation had the mildest effect on circulatory function consistent with normal dorsal aorta morphogenesis in these embryos ( Figure 2C ). At 55 hpf all kdrl um19 mutant embryos displayed normal circulation throughout the vascular system with no evidence of cardiac edema ( Figure 3E, H) . However, cranial hemorrhage was evident in approximately fifteen percent of all embryos, indicating a partially penetrant defect in vascular function in kdrl um19 mutants ( Figure 3G, H) . Consistent with our previous study, we observed variable circulatory defects in kdrl y17 mutant embryos, including some embryos with complete lack of circulation, presence of arteriovenous shunts between the dorsal aorta and posterior cardinal vein, and cranial hemorrhage ( Figure 3H and data not shown). Taken together, our results indicate that these alleles differentially affect blood vessel formation in the developing embryo.
Mutations in phospholipase c gamma 1 perturb artery development
Our previous work demonstrated that the y10 mutation ( Figure 1C , Table 1 ) lies in a splice donor site within the phospholipase c gamma 1 (plcg1) gene leading to a specific defect in artery development (Lawson et al., 2003) . Plcg1 mediates signaling downstream of a number of different receptor tyrosine kinases, including receptors for platelet derived growth factors (Pdgfs), fibroblast growth factors (Fgfs) and Vegf itself (Rhee, 2001; Wilde and Watson, 2001 ). Plcg1 interacts with phosphorylated tyrosine residues on an activated receptor tyrosine kinase via its SH2 domains. Subsequent activation of Plcg1 occurs through phosphorylation of tyrosine residues by the upstream receptor tyrosine kinase. This results in induction of Plcg1 catalytic activity leading to cleavage of phosphoinositide-4,5-bisphosphate (PIP2) to form inositol-3-phosphate (IP3) and diacylglycerol (DAG), second messengers that ultimately induce calcium release and activation of protein kinase C isoforms, respectively (Rhee, 2001 ). More recently, Plcg1 has been shown to transduce signals mediated by other upstream activators through interaction with its SH3 domain and can function in a catalytic domain independent manner in this regard (Patterson et al., 2002; Ye et al., 2002) .
We found that five additional mutants failed to complement plcg1 y10 or displayed genetic linkage to plcg1 (data not shown and Table 1 ). The y13, y15, and y16 alleles are point mutations in the plcg1 coding sequence that change conserved amino acid residues in relevant functional domains (Table 1 ; Fig. 4A and data not shown). Both plcg1 y13 and plcg1 y15 are in the X region of the split catalytic domain essential for lipase activity (Rhee, 2001) . In y13 mutant embryos C 412 is mutated to R, while y15 changes I 383 to N. In both cases, these residues are identical in the catalytic domains of related phospholipases across a wide variety of species ( Figure 4A and data not shown). The plcg1 y16 mutation changes R 557 to H in the N terminal Src homology 2 (SH2) domain. Based on crystal structure of the homologous SH2 domain in Src (Waksman et al., 1993) , this residue is important for direct binding to phosphorylated tyrosine residues. The y18 allele is a G to A transition in the consensus splice donor site (GT) for exon ENSDARE00000761392 (ENSEMBL, Zv7) and leads to a deletion in the X catalytic domain and premature truncation of the coding sequence ( Figure 4A and data not shown). The y19 mutation results in a small deletion in the plcg1 coding sequence, although we have not identified the genomic lesion in this mutant.
All plcg1 mutant embryos exhibited specific defects in artery development, but overall normal morphology was normal (data not shown). Wild type sibling embryos displayed a fully formed segmental artery network at 30 hpf ( Figure 4B ) while embryos mutant for plcg1 y13 ( Figure  4C ) or plcg1 y18 ( Figure 4E ) failed to form segmental artery sprouts. In addition, plcg1 y13 and plcg1 y18 mutant embryos do not initiate blood circulation. Consistent with the observed haploid phenotype (see Figure 1E ), the plcg1 y16 mutation caused weaker defects in artery development as all mutant embryos display partial segmental artery sprouts at 30 hpf (Fig. 4D) . Most embryos mutant for plcg1 y16 failed to initiate circulation, although we observed mutant embryos with arteriovenous shunts between the dorsal aorta and posterior cardinal vein (data not shown).
Plcg1 can mediate Vegf signaling through direct interaction with Kdr in human endothelial cells (Takahashi et al., 2001 ) and can also interact with the related Vegf receptor, Flt4 (Borg et al., 1995) . Accordingly, we have found that combined loss of Kdrl and Flt4 recapitulates segmental artery phenotype observed in plcg1 mutant zebrafish embryos (Covassin et al., 2006) . However, these observations do not rule out the possibility that Plcg1 mediates signaling through other signaling molecules through interaction with its SH3 domain. Therefore, to investigate this possibility, we performed an in vivo rescue assay using forms of plcg1 containing point mutations within the N-SH2 (R581K), C-SH2 (R689K) or SH3 (P837L) domains. Similar mutations in identical residues in mammalian plcg1 abrogate the function of these domains and prevent downstream signaling (Ji et al., 1999; Patterson et al., 2002; Ye et al., 2002) . We injected mRNA encoding mutant forms of plcg1 into embryos derived from an incross of plcg1 y18 heterozygous embryos ( Figure 4F ). We then assayed for segmental artery formation at 30 hpf and circulation at 55 hpf, followed by PCR-based genotyping. All uninjected plcg1 y18 mutant embryos failed to exhibit segmental artery formation or circulation, while injection of mRNA encoding wild type Plcg1 rescued these defects in the majority of mutant embryos ( Figure 4G, H) . Injection of mRNA encoding Plcg1 containing either SH2 mutations failed to rescue segmental artery formation or circulation ( Figure 4G, H) . By contrast, mutant embryos injected with plcg1 mRNA containing the P837L mutation in the SH3 domain were rescued to a similar degree as wild type plcg1. These results demonstrate that the SH3 domain is dispensable for Plcg1 signaling during vascular development. Taken together with the characterization of plcg1 mutants, our observations are consistent with a necessary role for Plcg1 catalytic activity downstream of receptor tyrosine kinases such as Kdrl and Flt4 during vascular development.
Signaling molecules that can be activated as a result of Vegf signaling through Plcg1 include Akt and components the MAP kinase cascade (Zachary and Gliki, 2001) . Additionally, recent observations in zebrafish suggest that MAPK signaling is important for artery development (Hong et al., 2006) . Therefore, we investigated whether activation of either of these pathways could rescue vascular defects downstream of plcg1. To activate the MAPK cascade, we expressed a version of mitogen activated protein kinase kinase 1 (MAP2K1) containing amino acid substitutions (Ser218>Glu and Ser222>Asp; referred to hereafter as actMAP2K1; Supplemental Figure 1 ) that lead to 20-fold increases in activity of its downstream substrate, MAPK1 (Mansour et al., 1994) . Accordingly, embryos injected with mRNA encoding a mCherrry fluorescent protein-actMAP2K1 fusion display overt defects in development as a consequence of ubiquitous MAPK activation (Supplemental Figure 2C-H) . To avoid these early developmental effects, we drove expression of mCherry-actMAP2K1 in endothelial cells using the fli1ep cis element in a Tol2-transposon backbone (Villefranc et al., 2007) . Wild type embryos expressing mCherry-actMAP2K1 displayed red fluorescence throughout the trunk vasculature ( Figure 5A-C) , including the segmental arteries. In some cases, segmental arteries expressing high levels of the transgene appeared to exhibit increased filopodial activity, while those expressing lower levels were normal ( Figure 5A, B) . In plcg1 y13 mutant embryos, cells expressing fli1ep:mCherry-actMAP2K1 could be found within blood vessels ( Figure 5D-F) . However, mCher-actMAP2K1-positive cells did not form segmental arteries, despite their ability to contribute to the dorsal roof of the aorta in plcg1 y13 mutant embryos (see arrows in Figure 5E , F). Similarly, we did not observe circulation in plcg1 y13 mutant embryos expressing fli1ep-driven mCher-actMAP2K1, even in cases of low transgene mosaicism (data not shown).
To determine if Akt could rescue vascular defects downstream of plcg1, we expressed a myristoylated form of this kinase that leads to its constitutive activation (referred to as mAkt, (Kohn et al., 1996) ). To monitor expression of mAkt, we generated a cassette containing the viral 2A sequence in between mAkt and monomeric Cherry fluorescent protein (mAkt-2A-mCher; Supplemental Figure 1 ), allowing expression of these two separate proteins from a single transcript (Provost et al., 2007) . As with activated MAP2K1, injection of mRNA encoding mAkt-2A-mCher led to overt defects on embryonic development (Supplemental Figure 2I-L) . Therefore, we again used the fli1ep element to drive expression of mAkt-2A-mCher in endothelial cells. As with actMAPK21, we were able to observe mAkt-2A-mCherexpressing cells in the wild type vasculature of Tg(fli1a:egfp) y1 embryos (data not shown). Similarly, endothelial cells expressing mAkt-2A-mCher could localize to the aorta, but failed to initiate segmental artery sprout formation in plcg1 y13 mutant embryos ( Figure 5G-I ) or rescue circulation (data not shown). Taken together, these results indicate that activation of either MAPK or Akt signaling alone does not appear to be sufficient downstream of plcg1 to rescue vascular development.
We have previously reported that plcg1 y10 mutant embryos display only partially penetrant defects in arterial endothelial differentiation, while defects in circulation and segmental artery formation are observed in all mutant embryos (Lawson et al., 2003) . To determine if the other alleles of plcg1 lead to similar arterial endothelial differentiation defects, we assayed artery marker gene expression in embryos at 24 hpf, followed by genotypic analysis to identify mutant and wild type siblings. We observed that differences in artery marker gene expression could be separated into three phenotypic classes in embryos derived from plcg1 mutant heterozygous incrosses: normal ( Figure 6A ), weak ( Figure 6B ), or absent ( Figure 6C ). Following genotyping, we found that all wild type sibling embryos displayed normal artery specific expression of both ephrinb2a and notch3 ( Figure 6D ). By contrast more than half of plcg1 y13 and plcg1 y18 mutant embryos displayed complete loss of or weak artery marker gene expression, although the remaining mutant embryos expressed normal levels ( Figure 6D ). Consistent with the weaker artery defects in plcg1 y16 mutants, we observed a higher proportion of ephrinb2a and notch3 expression in these embryos (Fig. 6D) .
The partially penetrant defects in artery differentiation suggested to us that maternally deposited plcg1 transcript (Tsang et al., 2004) could partially compensate for zygotic loss of plcg1 in our mutants. To investigate this possibility, we performed germline replacement (Ciruna et al., 2002) to generate adult zebrafish that would produce plcg1 homozygous null gametes. We then crossed maternal mutant (Mplcg1 y18 ) and paternal mutant (Pplcg1 y18 ) carriers and observed progeny embryos for defects in overall morphology, vascular function, and artery marker gene expression. Embryos derived from Mplcg1 y18 x Pplcg1 y18 crosses (referred to as MPZplcg1 y18 ) displayed relatively normal morphology at 30 hpf (Fig. 6E) . While collapsed brain ventricles (arrows in Figure 6E , F) were evident in MPZplcg1 y18 mutant embryos, other morphological landmarks within the brain, such as the mid-brain hindbrain boundary were evident, suggesting that Fgf signaling was normal (Reifers et al., 2000) . Incomplete filling of the ventricles has been observed in mutants lacking circulation (Lowery and Sive, 2005) and can be seen in kdrl um6 mutant embryos (see Figure 3B ). Within the trunk of MPZplcg1 y18 embryos, development of the neural tube, floor plate, and notochord, as well as pigmentation, appeared normal (Fig. 6G) . However, all embryos derived from Mplcg1 y18 x Pplcg1 y18 crosses failed to initiate circulation, displayed a disorganized dorsal aorta and posterior cardinal vein and exhibited cardiac edema at 55 hpf (data not shown). By contrast, embryos derived from a cross between a Mplcg1 y18 female and a wild type Tg(fli1a:egfp) y1 male yielded all normal embryos that did not exhibit any vascular defects ( Figure 6F , H, data not shown). To determine if maternal plcg1 could rescue arterial specification in the absence of zygotic gene function, we assayed artery maker gene expression (ephrinb2a and dll4) in MPZplcg1 y18 embryos. Interestingly, we observed consistent variation in the penetrance of artery differentiation defects between two different Mplcg1 y18 female carriers. However, in both cases loss of artery marker gene expression was more severe in MPZplcg1 y18 embryos than in zygotic plcg1 y18 ( Figure 6D ). Embryos derived from one of the Mplcg1 y18 female carrier failed to express either ephrinb2a or dll4, while nearly half of the embryos from the second Mplcg1 y18 female carrier displayed weak artery marker gene expression ( Figure 6D ). We did not observe normal artery marker gene expression in any MPZplcg1 y18 embryos. These results suggest that maternal plcg1 contribution alone is largely dispensable for embryonic development. However, in the absence of zygotic plcg1, maternal contribution appears capable of providing a compensatory signal that can rescue artery differentiation.
Plcg1 can mediate Vegf receptor signaling in endothelial cell lines (Takahashi et al., 2001 ) and our previous work suggests that plcg1 is required for Vegf responsiveness in zebrafish embryos (Lawson et al., 2003) . However, an endothelial cell autonomous function for plcg1 has not been demonstrated. Therefore, we performed mosaic analysis using cell transplantation in zebrafish embryos to investigate the requirement for plcg1 in endothelial cells. For this purpose, we utilized two endothelial cell specific transgenic lines. As a source of donor cells, we relied on Tg(fli1a:egfp) y1 transgenic embryos. For host embryos, we used Tg(fli1ep:dsredex) um13 transgenic embryos in which the fli1ep element (Villefranc et al., 2007) drives expression of the red fluorescent protein, dsRedExpress, in all endothelial cells. As a general cell lineage tracer, we injected all donor embryos at the 1-cell stage with Cascade Blue. At sphere stage, cells were removed from Tg(fli1a:egfp) y1 donor embryos and transplanted into similarly staged Tg(fli1ep:dsredex) um13 recipients (Supplemental Figure 3) . We then assayed for contribution of Egfp-positive donor cells in the red vasculature of host embryos between 25 to 28 hpf. We find that wild type Tg(fli1a:egfp) y1 donor cells are capable of contributing to all blood vessel types within the trunk vasculature when transplanted into wild type Tg(fli1ep:dsredex) um13 recipients ( Figure 7A , Table 2 ). To determine if plcg1 was required autonomously in endothelial cells, we generated Plcg1-deficient host by injection of a plcg1 Morpholino followed by transplantation as described (Supplemental Figure 3) . We observed that wild type Tg(fli1a:egfp) y1 cells could contribute to segmental arteries in embryos otherwise lacking plcg1, while host red fluorescent segmental arteries were not observed ( Figure 7B ). This result indicates that Plcg1 functions autonomously within endothelial cells to mediate segmental artery sprouting. To determine if plcg1 deficient cells could contribute to wild type blood vessels, we performed the converse transplantation experiment. In this case, we co-injected Plcg1 MO and Cascade Blue to generate plcg1-deficient Tg(fli1a:egfp) y1 donor embryos (Supplemental Figure 3) . In the resulting embryos, we failed to observe any plcg1 deficient Egfp-positive cells in segmental arteries (Table 2) . However, plcg1-deficient cells were capable of contributing to other trunk blood vessels, including the dorsal aorta and posterior cardinal vein ( Figure 7C , Table 2 ). Interestingly, we found that plcg1 deficient cells in dorsal aorta were more likely to contribute to the ventral wall than to the dorsal wall of this blood vessel ( Figure  7D) . Similarly, we observed that transplanted cells mutant for plcg1 y13 could localize the ventral wall of the aorta ( Figure 7E , Table 2 ).
Discussion
In this work we describe a forward genetic approach to identify vascular mutants using the zebrafish as a model system. Our screening strategy combined two particular aspects of the zebrafish model that proved beneficial: first, the use of a transgenic line expressing Egfp in endothelial cells allowing robust and direct visualization of blood vessel morphology in live embryos . Second, the ability to rapidly screen mutagenized genomes by generating haploid embryos from F1 females. Despite the haploid genotype in the embryos we were scoring, we found that this approach can reliably identify mutations affecting vascular development. We were able to identify several specific classes of vascular defects in haploid Tg(fli1a:egfp) y1 embryos, including loss of segmental artery formation as well as ectopic branching of these vessels. It was also possible to identify milder defects in segmental artery sprouting and these were consistent with phenotypes associated with hypomorphic mutations in kdrl and plcg1 in diploid embryos. We observed that the majority of putative haploid mutant phenotypes were recapitulated in diploid embryos. Furthermore, we eliminated many other vascular phenotypes during screening based on obvious morphological defects in other tissues. Consistently, the mutant phenotypes we observed in diploid Tg(fli1a:egfp) y1 embryos were specific to the vascular system. Thus, it is possible to utilize a transgenic haploid screening strategy in zebrafish to reliably identify mutations that affect tissue-specific morphogenetic processes. The increasing availability of cell type-specific transgenic lines should allow this approach to be applied toward the genetic analysis of morphogenesis or differentiation in other organs and tissues in the developing zebrafish embryo.
Several groups have previously utilized the zebrafish to identify mutations affecting cardiovascular function and morphogenesis. In initial large-scale mutagenesis screens, two groups working in parallel identified zebrafish mutants lacking normal circulation using simple visual inspection by light microscopy Stainier et al., 1996) . By using a twogeneration screening approach in which circulatory phenotypes were scored in the progeny of F2 families (a so-called "F3 screen"), these groups identified approximately 70 loci that affected cardiovascular function from nearly 6000 mutagenized genomes. More recently, Jin et al. have incorporated transgenic visualization of endothelial cells into an F3 screening strategy (Jin et al., 2007) . In this case, circulatory defects were first screened in F3 progeny of non-transgenic fish, followed by visualization of the vascular system via alkaline phosphatase staining. Identified F2 carriers were then crossed into the Tg(kdrl:egfp) s843 background (Jin et al., 2005) to visualize the vasculature in more detail. This approach led to the identification of 30 loci that affected blood vessel formation out of approximately 4000 genomes screened. In each screen, the number of identified loci also included mutants that affected other tissues, in addition to blood vessels. Given that our screen focused on blood vessel specific defects, the number of loci per mutagenized genome that we identified using the haploid transgenic approach are similar.
The central drawback to F3 screening approaches in zebrafish is that they are cost-and laborintensive, require significant amounts of tank space, and generally take up to 5 years to screen sufficient numbers of mutant genomes. The transgenic haploid screening approach we describe here can be performed by a small lab group within a much shorter time frame. Furthermore, confirmation of diploid phenotypes can be performed in a map-cross background, making preliminary genetic mapping much more rapid than standard F3 screens. An obvious drawback of the haploid approach is the limitation on possible phenotypes that could be observed in a haploid embryo. In addition, haploid embryos display overt developmental abnormalities and some mutant phenotypes may be adversely affected by gene dosage. That being said, the majority of phenotypes we observed in haploid embryos were evident in diploids and we were able to identify several different phenotypic classes indicating that our screening approach was robust and reliable.
Plcg1 has been implicated in a variety of signaling cascades in a number of different cell types (Rhee, 2001; Wilde and Watson, 2001) . In most cases, Plcg1 functions downstream of receptor tyrosine kinases through a canonical pathway that entails binding of the Plcg1 SH2 domains to phosphorylated tyrosine residues within activated receptors, phosphorylation of tyrosine residues on Plcg1 by the upstream kinase, and subsequent induction of Plcg1 catalytic activity (Rhee, 2001 ). More recently, several studies have revealed new signaling roles for Plcg1 independent of its lipase activity (Patterson et al., 2002; Ye et al., 2002) . However, the relevant mode of Plcg1 signaling in vivo and during embryonic development is not clear. Previously, we had found that plcg1 deficient zebrafish embryos displayed specific defects in artery development and failed to respond to exogenous Vegf (Lawson et al., 2003) . Similar vascular defects have been observed in plcg1 null mouse embryos (Liao et al., 2002) further suggesting a primary role for plcg1 during Vegf signaling and/or vascular development. The specificity of these developmental defects had been surprising based on the extensive range of signaling processes in which plcg1 was known to play a role. While maternal compensation could explain the specificity of these embryonic defects, we find that this is not the case. Zebrafish embryos lacking maternal plcg1 develop normally and those that lack zygotic, maternal, and paternal, plcg1 proceed through gastrulation and are morphologically indistinguishable from zygotic mutants. We did not observe phenotypes associated with deficiency in other receptor tyrosine kinase signaling pathways that act early in development, such as Fgf (Reifers et al., 1998; Tsang et al., 2004) in any of these cases. These observations suggest that the primary role of plcg1 during animal development is to mediate development of the vascular system. Furthermore, our allelic series and structure/function analysis indicate a canonical mode of Plcg1 signaling downstream of Vegf receptors. Mutations within conserved residues of the Plcg1 catalytic domain result in similar defects associated with the putative null y18 allele, suggesting that catalytic activity is indispensable for Plcg1 function during vascular development. Furthermore, mutation of the N-SH2 domain leads to similar defects while Plcg1 bearing mutations in either of the SH2 domains fails to rescue the plcg1 mutant phenotype. Consistent with its presumed role downstream of the Vegf receptors, we demonstrate that plcg1 function is required autonomously within endothelial cells for proper segmental artery development and artery differentiation. Taken together with our previous observations that plcg1 mutant embryos fail to respond to exogenous Vegf (Lawson et al., 2003) , these results indicate that the primary role for plcg1 during development is to transduce Vegf signaling during blood vessel formation.
Several lines of evidence indicate that the Vegf signaling pathway is providing distinct signals to endothelial cells through Plcg1 at different points during vascular development. We have previously shown that kdrl and plcg1 are essential for artery differentiation or specification (Lawson et al., 2003; , a process that is known to occur during midsomitogenesis stages prior to formation of the dorsal aorta (Zhong et al., 2001) . Our findings that maternal plcg1 provides a compensatory signal for differentiation but not morphogenesis, which occurs during later stages, further supports the action of a Kdrl/Plcg1 signaling pathway during this earlier time point. During later segmental artery morphogenesis both kdrl and the zebrafish Vegf receptor-3 ortholog, flt4, appear to act through plcg1 (Covassin et al., 2006; Lawson et al., 2003) as combined loss of these receptors recapitulates the segmental artery and circulatory defects observed in plcg1 mutant embryos. Whether the different combination of activating receptors (Kdrl versus Kdrl with Flt4) during differentiation and morphogenesis elicit quantitative or qualitative differences in signaling through Plcg1 is not known at this time. The compensatory role of maternal Plcg1 at earlier time points may be most simply explained by a lower threshold of activation required for differentiation versus morphogenesis. In this case, Vegf signaling through Kdrl would lead to lower Plcg1 activity than that associated with both Kdrl and Flt4 during segmental artery sprouting ( Figure 8A ); in this case higher Plcg1 activity can promote active sprouting, and presumably concomitant differentiation, while lower levels promote differentiation only. Alternatively, the formation of different signaling complexes between the receptors and Plcg1 in these two settings may lead to the activation of distinct downstream signaling molecules and corresponding cellular output ( Figure 8B ). This possibility would be consistent with the additional role of Plcg1 as an adaptor protein to mediate downstream signaling molecules (Wilde and Watson, 2001 ). In either case, it is likely that distinct downstream effector molecules are subsequently acting to drive artery differentiation or morphogenesis downstream of Plcg1.
Our characterization of kdrl alleles would support the existence of qualitatively distinct signaling outputs in these different developmental contexts. The kdrl um6 mutation leads to the most severe defects in both segmental artery formation and circulatory function, as well as cranial hemorrhage in some heterozygous carriers, suggesting that this mutation acts as a mild dominant negative. The severity of the morphogenesis defects in these mutants as compared to the null kdrl um19 allele suggests that the um6 mutant receptor may block signaling of multiple Vegf receptors, including flt4, which can heterodimerize with Vegfr-2 in human endothelial cell lines (Alam et al., 2004) . The milder effect of the kdrl y17 mutation, which eliminates kinase activity (Covassin et al., 2006) , is somewhat surprising in this regard since similar mutations in related receptors yield dominant negative forms of these molecules (Dumont et al., 1994; Reith et al., 1993; Reith et al., 1990) . Segmental artery formation is more robust in kdrl y17 mutants when compared to the null phenotype raising the intriguing possibility that the Kdrl receptor can function in a kinase independent manner during segmental artery sprouting. Despite the loss of kinase activity, the Kdrl y17 receptor could still function as an adaptor or substrate for other kinases, such as Flt4, allowing sufficient, albeit compromised, activation of plcg1 and relatively normal segmental artery formation. In this case, the dominant negative um6 mutation would be predicted to block the interaction between Kdrl and Flt4, or prevent interaction with downstream effectors. This model would also be consistent with the effects of y17 on dorsal aorta morphogenesis, which appear more severe than those associated with kdrl um19 . While flt4 and kdrl are co-expressed in segmental artery tip cells, there is only transient co-expression of both transcripts in the dorsal aorta, followed by potent downregulation of flt4 expression. Formation of the dorsal aorta may proceed through the independent function of these receptors and therefore requires kinase activity of the Kdrl receptor. Taken together, our results suggest that Vegf/Plcg1 signaling is acting in distinct signaling contexts during artery differentiation, dorsal aorta morphogenesis and segmental artery sprouting. Further identification of additional alleles in kdrl, as well as mutations in flt4, will undoubtedly be helpful to dissect the diverse genetic interactions of these receptors and to identify downstream effectors that mediate each of these processes.
The zebrafish has proven to be an ideal model to study vascular development. The ability to perform forward genetic screens for vascular mutants has led to the identification of novel genes and new insights on how blood vessels form during embryonic development. Our demonstration that haploid transgenic screening allows reliable identification of vascular mutants will facilitate future screening for new genes affecting this blood vessel formation. By incorporating new transgenic lines that are more lineage-restricted within the vasculature, it would be possible to further expand the range of phenotypic classes that could be identified. For example, use of artery or vein restricted transgenes may yield additional classes of mutations that affect endothelial differentiation without overt defects in vascular morphogenesis; these mutants would not have been easily identified in our screen. While the forward genetic approach has proven valuable, it is likely that new reverse genetic approaches will begin to be more widely applied. The size of the zebrafish genome precludes saturation screening and numerous mutants have now been repeatedly isolated from several different screens. The number of genes expressed in cardiovascular tissue in zebrafish embryos numbers well over 100, with many more likely to be identified. Moving forward, a concerted effort that integrates focused transgene-assisted forward genetic screens, along with reverse approaches that take advantage of new technologies (e.g. zinc finger nucleases for genome modification) will allow for a comprehensive genetic analysis of endothelial cell development and vascular morphogenesis.
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Refer to Web version on PubMed Central for supplementary material. Defects in circulatory function in kdrl mutants. A-G. Transmitted light images of wild type and kdrl mutant zebrafish embryos at 55 hours post fertilization. Lateral views, anterior to the left, dorsal is up. A. Wild type sibling embryo. Scale bar is 250 μM. B. kdrl um6 mutant embryo displaying cardiac edema (white arrow). C. Eye (indicated) and forebrain region of wild type sibling embryo. Scale bar is 50 μM. D. Cranial hemorrhage (white arrows) in a heterozygous carrier of the kdrl um6 allele. E. kdrl um6 heterozygous embryo. F. kdrl um19 mutant embryo. G. Eye and forebrain region of a kdrl um19 mutant embryo. A cranial hemorrhage is indicated by the white arrow. H. Quantification of circulatory defects in clutches of embryos derived from in-crosses of um6, um19, and y17 heterozygous carriers; circ -circulation, shunt -abnormal circulatory connection between dorsal aorta and posterior cardinal vein, hem -cranial hemorrhage. plcg1 is required for segmental artery formation. A. Functional domains within Plcg1. PHpleckstrin homology domain; X, Y -split catalytic domains; SH2 -src homology-2 domains; SH3 -src homology 3 domain. Residues affected by the y13 and y16 mutations are outlined in red and aligned with conserved sequences from other species (Dr -zebrafish, Hs -human, Dm -Drosophila, Mm -mouse). The y18 allele leads to a truncation in the X-catalytic domain. B-E. Confocal fluorescent micrographs of trunk blood vessels at 30 hours post fertilization. Lateral views, anterior to the left, dorsal is up. B. Wild type sibling embryo. Scale bar is 50 μM. C. Loss of segmental arteries in a plcg1 y13 mutant embryo. D. Partial segmental arteries (white arrows) in a plcg1 y16 mutant embryo. E. plcg1 y18 mutant embryo. F. Position of point mutations engineered into rescue constructs in the Plcg1 SH2 and SH3 domains. G. Graph indicating proportion of embryos displaying segmental artery or DLAV formation following injection with mRNA encoding the indicated Plcg1 construct. H. Graph indicating proportion of embryos displaying partial or complete circulation following injection with mRNA encoding the indicated Plcg1 construct; SeA -segmental arteries, DLAV -dorsal longitudinal anastamotic vessel, circ -circulation, partial -shunt between dorsal aorta and posterior cardinal vein. Artery differentiation defects in plcg1 mutants. A-C. Classification schema to categorize level of artery marker gene expression in plcg1 mutant embryos. Differential interference contrast (DIC) images of zebrafish embryo trunks following whole mount in situ hybridization to detect ephrinb2a (efnb2a). A. Normal ephrinb2a expression in the dorsal aorta (white arrow). B. Weak ephrinb2a in distinct patches within the dorsal aorta (white arrows). C. Loss of dorsal ephrinb2a expression classified as "absent". D. Quantification of artery marker gene expression in y13, y16, y18 and MPZy18 mutant embryos. E, F. Transmitted light images of embryos at 30 hpf. Scale bar is 250 μM. G, H. DIC images of embryos at 30 hpf. E-H., Lateral views, anterior to the left, dorsal is up. E, G. MPZplcg1 y18 mutant embryo. Scale bar is 30 μM; nt -neural tube, fp -floor plate, nc -notochord. Asterisked bracket denoted absence of defined dorsal aorta or posterior cardinal vein. F, H. Mplcg1 y18 ; Tg(fli1a:egfp) y1 mutant embryo; DA -dorsal aorta, indicated by a bracket. Model of possible quantitative or qualitative differences of signaling through Plcg1. Table 1 Segmental artery mutants identified by haploid transgenic screening into wt, n=3.
